Emergency treatment of status asthmaticus with enoximone

British Journal of Anaesthesia

Volumn 112, Issue 6, 2014, Pages 1105-1108

  Beute, J ^a  

^a Department of Anesthesiology Intensive Care MC Groep Lelystad Dronten Emmeloord   (Netherlands)

Author keywords

asthma; enoximone; intensive care; respiratory factors

Indexed keywords

AMINOPHYLLINE; ANESTHETIC AGENT; ENOXIMONE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; KETAMINE; SALBUTAMOL; STEROID;

ABSENCE OF SIDE EFFECTS; ACIDOSIS; ADOLESCENT; ADULT; AGED; AMBULANCE; ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; ASTHMATIC STATE; ATOPIC DERMATITIS; BRONCHODILATATION; CAPILLARY BLOOD; CLINICAL ARTICLE; CONSCIOUSNESS; COST CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EMERGENCY TREATMENT; EMERGENCY WARD; ENDOTRACHEAL INTUBATION; FEMALE; FLAIL CHEST; FOLLOW UP; HUMAN; HYPERCAPNIA; INHALATION; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; MEDICAL HISTORY; MEDICAL NEBULIZER; MULTICENTER STUDY; NEBULIZATION; PANIC; PRIORITY JOURNAL; RESPIRATORY ARREST; RESPIRATORY TRACT PARAMETERS; SEIZURE; STEROID THERAPY; TACHYCARDIA; TACHYPNEA; URINE INCONTINENCE; WHEEZING;

ASTHMA; ENOXIMONE; INTENSIVE CARE; RESPIRATORY FACTORS;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; EMERGENCY TREATMENT; ENOXIMONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; STATUS ASTHMATICUS; TREATMENT OUTCOME;

EID: 84900993020     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu048     Document Type: Article

References (23)

1. Torphy TJ.Action ofmediatorsonairwaysmoothmuscle: Functional antagonism as a mechanism for bronchodilator drugs. Agents Action 1988; 23 (Suppl.): 37-53
2. Torphy TJ, Hay DWP. Biochemical regulation of airway smooth muscle tone: An overview. In: Townley RG, Agrawal DK, eds. Airway Smooth Muscle: Modulation of Receptors and Response. Boca Raton: CRC Press, 1990; 39-68
3. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 1991; 46: 512-23
4. Fujimura M, Kamio Y, Myou S, Hashimoto T, Matsuda T. Effect of a phosphodiesterase 3-inhibitor, Cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma. Int Arch Allergy Immunol 1997; 114: 379-84 (Pubitemid 27504107)
5. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricularmuscle. Circulation 1986; 73(Suppl. 3): III-117-33
6. Roebel LE, Dage RC, Cheng HC, Woodward JK. Characterization of the cardiovascular activities of a new cardiotonic agent: MDL 17,043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol 1982; 4: 721-9 (Pubitemid 12019448)
7. Underwood DC, Kotzer CJ, Bochnowicz S, et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994; 270: 250-9 (Pubitemid 24229635)
8. British Guideline on the Management of Asthma. May 2008, revised January 2012. Available from http://www.sign.ac.uk/pdf/sign101.pdf (accessed on several occasions between 2008 and 2013)
9. World Health Organization. Facts and News. Available from http://www.who.int/mediacentre/factsheets/fs307/en (accessed on several occasions between 2008 and 2013)
10. Statistic Brain-Percentages-Numbers-Financials-Rankings. Available from http://www.statisticbrain.com/asthma-statistics (accessed on several occasions between 2008 and 2013)
11. Asthma and Allergy Foundation of America. Available from http://www.aafa.org (accessed on several occasions between 2008 and 2013)
12. Hart SP. Should aminophylline be abandoned in the treatment of acute asthma in adults? QJM 2000; 93: 761-5
13. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Libr 2009 doi: 10.1002/14651858.CD002742.pub2
14. BarnesPJ. Pulmonary Perspectives:Theophyline.AmJResp CritCare 2013; 188: 901-6
15. Lehtonen LA, Antila S, Pentikäinen PJ. Pharmacokinetics and pharmocodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004; 43: 187-203 (Pubitemid 38293791)
16. Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: Modulation byendogenous effectors, drugs and disease states. Pharmacol Rev 1997; 49: 1-51
17. Sircar I, Steffen RP, Bobowski G, et al. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol- 1-yl)phenyl]ethenyl]-3(2H)-pyridazinones: A novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J Med Chem 1989; 32: 342-50 (Pubitemid 19061877)
18. MacDonnell KF, Moon HS, Sekar TH, Ahlu-walia MP. Extracorporeal membrane oxygenator support in a case of severe status asthmaticus. Ann Thorac Surg 1981; 31: 171-5 (Pubitemid 11173191)
19. Leiba A, Bar-Yosef S, Bar-DayanY,Weiss Y, Segal E. Earlyadministration of extracorporeal life support for near fatal asthma. IMAJ 2003; 5: 600-2 (Pubitemid 36992260)
20. Farmacotherapeutisch Kompas. Onafhankelijke geneesmiddelinformatie voor professionals in de zorg-searchword 'enoximone'. Available from http://www.fk.cvz.nl (accessed 9 April 2013)
21. Kereiakes D, Chatterjee K, ParmleyWW, et al. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol 1984; 4: 884-9 (Pubitemid 15206635)
22. Rubin SA, Tabak L. MDL 17043: Short-and long-term cardiopulmonary and clinical effects in patients with heart failure. J Am Coll Cardiol 1985; 5: 1422-7 (Pubitemid 15069519)
23. Shah PK, Devendra KA, Hulse S, Shellock F, Swan HJC. Inotropic therapyfor refractorycongestive heart failurewith oral fenoximone (MDL-17,043): Poor long-term results despite early hemodynamic and clinical improvement. Circulation 1985; 71: 326-31 (Pubitemid 15157093)